Last reviewed · How we verify
Ceftaroline Fosamil — Competitive Intelligence Brief
marketed
Infectious Disease
Small molecule
Live · refreshed every 30 min
Target snapshot
Ceftaroline Fosamil (CEFTAROLINE) — Abbvie. Ceftaroline works by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Ceftaroline Fosamil TARGET | CEFTAROLINE | Abbvie | marketed | 2012-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Ceftaroline Fosamil CI watch — RSS
- Ceftaroline Fosamil CI watch — Atom
- Ceftaroline Fosamil CI watch — JSON
- Ceftaroline Fosamil alone — RSS
Cite this brief
Drug Landscape (2026). Ceftaroline Fosamil — Competitive Intelligence Brief. https://druglandscape.com/ci/ceftaroline. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab